Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: 8 weeks of home based use.; Device
Lead sponsor: Michigan State University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Post Operative Pain
Interventions: IV Acetaminophen; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: ASTHMAXcel Voice platform; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hypertension, Retinal Disorder, Cognitive Impairment
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more

Conditions: Age-related Macular Degeneration (AMD)
Interventions: LMG324, Ranibizumab 0.5 mg, Sham; Biological
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Post Traumatic Stress Disorder
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Myasthenia Gravis
Interventions: Ublituximab, Placebo; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Colorado Springs, Colorado • Clearwater, Florida • Maitland, Florida + 3 more

Conditions: Dermatitis, Psoriasis
Interventions: Narrowband Ultraviolet B (TL-01UVB) Therapy, Topical Psoralen plus ultraviolet A (PUVA); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atopic Keratoconjunctivitis
Interventions: DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: anamorelin HCl, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more

Conditions: Alopecia
Interventions: Setipiprant, Placebo, Finasteride; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more

Conditions: Heart Defects, Congenital
Interventions: nesiritide, milrinone, placebo; Drug
Lead sponsor: John M Costello; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Nutritional and Dietary Manipulation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Fractures, Bone, Deformity; Bone
Interventions: A treatment group that will watch a non-VR video via an iPad, A treatment group that will have headset on and will watch a non-VR video, A treatment group that will be immersed in the VR game (Bear Blast) via the headset.; Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 4 Years to 14 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Sleep, Anxiety, Depression, Pain
Interventions: fsCBD Cannabidiol, bsCBD Cannabidiol, Placebo; Drug
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 60 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 5,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 176
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more

Conditions: Dental Pain
Interventions: Acetaminophen ER, Placebo; Drug
Lead sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.; Industry
Eligibility: 17 Years to 45 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Primary Sjögren's Syndrome
Interventions: AMG 557/MEDI5872, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: San Francisco, California • Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: azelaic acid pre foam formulation, Vehicle pre foam formulation, Water; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Contraception
Interventions: Treatment group: receives counseling phone call intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years and older · Female only
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Pain
Interventions: VX-993, HB/APAP, Placebo (matched to VX-993), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more

Search by objective public record fields.

Efficacy of the Apollo System for Children With ADHD

RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain

ASTHMAXcel Voice Study

DETECT and Retinal Outcomes in Hypertension

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery

Ketogenic Diet in Patients With Heart Failure

Virtual Reality Distraction During Outpatient Pediatric Orthopedic Procedures

Cannabidiol and Older Adult Cannabis Users

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Study of Long-Acting Acetaminophen in Postoperative Dental Pain

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

RCT: Can a Single Counseling Phone Call Improve Contraception After an Abortion?

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy